

safety of niraparib vs PBO in older patients. The primary endpoint was PFS assessed by blinded independent central review.

Results Of 733 enrolled pts, 444 were <65 yo (297 niraparib, 147 PBO), and 289 were ≥65 yo (190 niraparib, 99 PBO). Efficacy was comparable in pts <65 yo (HR 0.61; 95% CI 0.47–0.81) and ≥65 yo (HR 0.53; 95% CI 0.39–0.74) who received niraparib compared with PBO. Any-grade and grade ≥3 treatment emergent adverse events were similar across age groups (table 1). Grade ≥3 thrombocytopenia events in pts <65 yo were reported in 43% of pts receiving a FSD and 18% of pts receiving ISD. In pts ≥65 yo, the values were 57% and 26%, respectively. Patient reported outcomes (PROs) and quality of life (QOL) were similar in both age groups as assessed by FOSI and EQ-5D-5L.

Conclusion Niraparib efficacy, safety, and QOL were similar in compared age groups. Implementation of an ISD regimen improved rates of grade ≥3 thrombocytopenia events in older pts.

Disclosures Funding: GlaxoSmithKline

NCT number: NCT02655016

Encore statement: This data is presented on behalf of the original authors with their permission. Presented at the European Society for Medical Oncology (ESMO) Annual Meeting, September 19–21, 2020, Virtual.

Dr. Dahlstrand reports personal fees from AstraZeneca and Roche.

Dr. Pothuri reports grants, personal fees and non-financial support from GSK; Advisory Board fees from AstraZeneca and Clovis Oncology.

Dr. Graybill reports personal fees from GSK.

Dr. McCormick has nothing to disclose.

Dr. de La Motte Rouge reports personal fees and non-financial support from ASTRAZENECA, MSD, and Roche; personal fees from Clovis Oncology and GlaxoSmithKline; and grants, personal fees, and non-financial support from Pfizer.

Dr. Heitz reports non-financial support from NewOncology; Personal fees from Roche, AstraZeneca, Clovis, Tesaro, and PharmaMar.

Dr. Monk reports consulting and advisory role at Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Cerulean Pharma, Amgen, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, VBL Therapeutics, Takeda, Samumed, Oncomed, OncoSec, ChemoID, Geistlich Pharma, Eisai and Chemocare; Speakers' bureau at Roche/Genentech, AstraZeneca, Janssen, Clovis Oncology and GSK; Honoraria from Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Pethera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics, Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, ChemoID, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Genentech, Lilly, Janssen, Array BioPharma, GSK, Morphotek, Pfizer, Advaxis, AstraZeneca, Immunogen, Regeneron, and Nucana.

Dr. González-Martín reports personal fees and non-financial support from AstraZeneca; Grant and personal fees from GSK, Clovis Oncology, Roche Holding AG, Merck & Co., Inc., Genmab, INMUNOGEN, Pharma Mar, S.A., and Oncinvent AS.

Drs Li and Gupta are employees of GlaxoSmithKline.

EFFICACY OF NIRAPARIB THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER BY BRCAWT STATUS: PRIMA/ENGOT-OV26/GOG-3012 STUDY

¹Elena Ioana Braicu, ²Bhavana Pothuri, ³Jose Alejandro Pérez-Fidalgo, ⁴David O'malley, ⁵Brigitte Honhon, ⁶Whitney Graybill, ⁷Michel Fabbro, ⁸Hanna Dahlstrand, ⁹Divya Gupta, ¹⁰Bradley J Monk. ¹Charité Medical University; ²Gynecologic Oncology Group (Gog); Perlmutter Cancer Center, Nyu Langone Health; Department of Obstetrics/Gynecology; ³Incliva University Hospital of Valencia, Ciberonc; Department of Medical Oncology; ⁴The Ohio State University – James CCC; ⁵Grand Hôpital De Charleroi; Department of Oncology; ⁶Gog; Medical University of South Carolina; Gynecologic Oncology; ⁷Institut du Cancer de Montpellier; ⁸Uppsala University; Uppsala University Hospital; Department of Immunology, Genetics, and Pathology; Department of Oncology; ⁹Glaxosmithkline; ¹⁰Arizona Oncology (US Oncology Network), University of Arizona College of Medicine

10.1136/ijgc-2020-ESGO.124

Introduction/Background Niraparib is a poly(ADP-ribose) polymerase inhibitor approved for maintenance treatment of patients with newly diagnosed advanced or platinum-sensitive, recurrent ovarian cancer (OC). Niraparib is also approved in the United States for the treatment of patients with OC who received ≥3 lines of therapy and whose cancer is either BRCA mutated or homologous recombination deficient (HRd) platinum-sensitive disease. The PRIMA/ENGOT-OV26/GOG-3012 trial showed that niraparib significantly improves progression-free survival (PFS) in patients with newly diagnosed advanced OC that responded to first-line platinum-based chemotherapy (hazard ratio, 0.62; 95% CI, 0.50–0.76). Here we report the efficacy of niraparib in patients by BRCA wild-type (BRCAwt) status.

Methodology This double-blind, placebo-controlled, phase 3 trial evaluated niraparib in patients with newly diagnosed, advanced, high-grade serous or endometrioid ovarian, primary peritoneal or fallopian tube cancer with a complete response (CR) or partial response (PR) to first-line platinum-based chemotherapy. Patients were stratified by best response to the first-line chemotherapy (CR/PR), receipt of neoadjuvant chemotherapy (yes/no), and homologous recombination status (deficient/proficient and not determined). Patients were randomised 2:1 to receive either niraparib or placebo once daily. The primary endpoint of PFS, assessed by blinded independent central review, was analysed using a stratified log-rank test and Cox proportional hazards model and hierarchically tested in HRd patients, then the overall population. BRCA and HRd status were determined by tumour samples at screening via the myChoice[®] test (Myriad, Salt Lake City, Utah). The prespecified BRCAwt subgroup PFS analysis was performed using a stratified log-rank test and Cox proportional hazards model and using Kaplan-Meier methodology. BRCAwt subgroups included the intention-to-treat/BRCAwt (all patients who were homologous recombination not determined [HRnd]/BRCAwt, HRd/BRCAwt, and homologous recombination proficient [HRp]/BRCAwt); subgroup analyses on the HRd/BRCAwt and HRp/BRCAwt were performed.

Results Of 733 randomised patients, 473 (64.5%) had BRCAwt tumours (74 patients had unknown BRCA status). Of these 473, 150 (31.7%) had HRd/BRCAwt tumours, 249 (52.6%) had HRp/BRCAwt tumours, and 74 (15.7%) had HRnd/BRCAwt tumours. Niraparib-treated patients with BRCAwt tumours had a clinically meaningful PFS benefit regardless of homologous recombination status (table 1).

Abstract 364 Table 1

	ITT/ <i>BRCA</i> wt* n=473	HRd/ <i>BRCA</i> wt n=150	HRp/ <i>BRCA</i> wt n=249
Hazard ratio (95% CI),	0.69 (0.54–0.88)	0.50 (0.31–0.83)	0.68 (0.49–0.94)
mPFS, months			
Niraparib	10.9	19.6	8.1
Placebo	7.4	8.2	5.4
ΔmPFS, months	3.5	11.4	2.7
*Includes patients who were HRnd but known to be <i>BRCA</i> wt. HRd, homologous recombination deficient; HRnd, homologous recombination not determined; HRp, homologous recombination proficient; ITT, intention-to-treat; mPFS, median progression-free survival; wt, wild-type.			

Conclusion Niraparib improved PFS when utilised as maintenance therapy after front-line treatment of OC in patients with *BRCA*wt tumours, including in the most difficult to treat subgroup of patients with *BRCA*wt and HRp tumours.

Disclosures Dr. Braicu reports honoraria from AstraZeneca, Tesaro, GSK, Roche Pharma, Clovis and MSD; consulting or advisory roles at AstraZeneca, Tesaro, GSK, Roche Pharma, Clovis, MSD, Abbvie, Eisai, Immunogen, Takeda; institutional research funding from Roche Diagnostics and Takeda; and travel, accommodation and expenses from AstraZeneca, RochePharma, Clovis, and MSD.

Dr. Pothuri reports grants, personal fees and non-financial support from GSK; Advisory Board fees from AstraZeneca and Clovis Oncology.

Dr. Alejandro Perez-Fidalgo reports speaker fees from GSK, AstraZeneca, Clovis, and Roche; advisory fees from GSK, AstraZeneca, Clovis, Abilify Pharma, Clinigen, Roche, and Amgen; grant from GSK; and travel fees from AstraZeneca and Roche.

Dr. O'Malley reports personal fees from Immunogen, Eisai, Agenus, GSK : Consultant/Advisory Board for Clovis, Ambry, Abbvie, Janssen/J&J, Regeneron, Novacure, Myraid Genetics, Tarveda, Amgen, VentiRx, Array BioPharma, EMD Serono, Ergomed; Steering committee for Genentech/Roche and Merck; Institutional funding from Ajinomoto Inc, Ludwig Cancer Research, Stemcentrx, Inc, CERULEAN PHARMA, GOG Foundation, BMS, Serono Inc, TRACON Pharmaceuticals, Yale University, New Mexico Cancer Care Alliance, INC Research, Inc., Inventiv Health Clinical, Iovance Biotherapeutics, Inc, and PRA International.

Dr. Graybill reports personal fees from GSK.

Dr. Dahlstrand reports personal fees from AstraZeneca and Roche.

Dr. Monk reports consulting and advisory role at Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Cerulean Pharma, Amgen, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, VBL Therapeutics, Takeda, Samumed, Oncomed, OncoSec, ChemoID, Geistlich Pharma, Eisai and Chemocare; Speakers' bureau at Roche/Genentech, AstraZeneca, Janssen, Clovis Oncology and GSK; Honoraria from Merck, GSK, Roche/Genentech, AstraZeneca, Advaxis, Immunogen, NuCana BioMed, Clovis Oncology, Pfizer, Mateon Therapeutics, Precision Oncology, Perthera, Abbvie, Myriad Pharmaceuticals, Incyte, Janssen, Amgen, Genmab, Samumed, Takeda, VBL Therapeutics,

Puma Biotechnology, Immunomedics, Conjupro Biotherapeutics, Agenus, OncoQuest, ChemoID, Geistlich Pharma, Eisai and Chemocare; and Research funding from Novartis, Amgen, Genentech, Lilly, Janssen, Array BioPharma, GSK, Morphotek, Pfizer, Advaxis, AstraZeneca, Immunogen, Regeneron, and Nucana.

Drs. Honhon and Fabbro have nothing to disclose.

Dr. Gupta is an employee of GlaxoSmithKline.

366

FEASIBILITY STUDY OF A NETWORK META-ANALYSIS AND UNANCHORED POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON OF NIRAPARIB, OLAPARIB, AND BEVACIZUMAB AS MAINTENANCE THERAPIES IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER

¹Domenica Lorusso, ²Holly Guy, ³Jean Hamilton, ⁴Yevgeniy Samyshkin, ⁵Karin Travers, ⁶Carol Hawkes, ⁶Robert L Coleman. ¹Gynaecology Oncology Unit, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy; ²Fiecon, London, UK; ³School of Health and Related Research, University of Sheffield, Sheffield, UK; ⁴GlaxoSmithKline, London, UK; ⁵GlaxoSmithKline, Waltham, MA, USA; ⁶University of Texas MD Anderson Cancer Center, Houston, TX

10.1136/ijgc-2020-ESGO.125

Introduction/Background Although randomised controlled trials (RCTs) have demonstrated the benefit of PARP inhibitors and bevacizumab as monotherapies and combination therapies, there is limited direct head-to-head evidence of their relative clinical efficacy.

In the PRIMA study, niraparib demonstrated a clinically significant improvement in progression-free survival (PFS) compared with placebo, as a first-line (1L) ovarian cancer (OC) maintenance therapy.

The objectives of the study were to assess feasibility of an indirect treatment comparison (ITC) and a population-adjusted indirect treatment comparison (PAIC) for estimating the relative efficacy of niraparib compared with olaparib, olaparib plus bevacizumab, and bevacizumab as maintenance following 1L chemotherapy in OC. The study focused on fully powered statistical cohorts.

Methodology Trials included in the ITC analysis were based on a systematic literature review conducted in February 2020.

Guidelines from the Cochrane Handbook for Systematic Reviews of Interventions were used to assess the level of heterogeneity across the studies in terms of designs, population characteristics, treatment arms and outcome measures.